The Union Health Ministry has sent out a fresh advisory to all states and Union Territories, warning against the unchecked use of stem cell therapy outside approved medical conditions. The directive, dated September 16, stresses that hospitals and doctors offering, prescribing or advertising such treatments beyond sanctioned indications could be held guilty of professional misconduct.
This move follows a Supreme Court ruling delivered on January 30, 2026, in the case of Yash Charitable Trust and others versus Union of India, which had flagged the need for tighter oversight of how stem cell procedures are marketed and administered across the country.
One of the most significant aspects of the advisory is Autism Spectrum Disorder. The Ministry has reiterated that no form of stem cell treatment can be offered to autistic patients as routine clinical care. Any such use must happen strictly within the confines of officially sanctioned clinical trials, in line with the National Guidelines for Stem Cell Research first framed in 2017 by the Indian Council of Medical Research and the Department of Biotechnology.
For other health conditions, stem cell therapy will continue to be permitted only for the specific list of diseases that the Ministry has formally cleared for standard treatment. States have been asked to pass these instructions down to district-level health regulators as well as both government and private clinical establishments engaged in stem cell research, treatment or promotion, ensuring the rules are followed without exception.
The advisory also spells out what happens when clinics don’t comply. Under the Supreme Court’s January ruling, violations can trigger disciplinary action for professional misconduct under existing medical council regulations, along with penalties and even cancellation of registration under the Clinical Establishments Act of 2010.
Adding further weight to this push, the National Medical Commission had already issued its advisory on September 5, restating that stem cell therapy must be limited to conditions with proper regulatory approval.
Together, these steps signal a clear tightening of the noose around clinics offering unproven or unapproved stem cell “cures”, particularly those targeting vulnerable groups, such as families seeking autism treatment.